Comparative analysis of adverse events between infliximab and adalimumab in Crohn's disease management: a Brazilian single-centre experience
INTRODUCTION: Data is scarce regarding adverse events (AE) of biological therapy used in the management of Crohn's Disease (CD) among Brazilian patients. OBJECTIVES: To analyse AE prevalence and profile in patients with CD treated with Infliximab (IFX) or Adalimumab (ADA) and to verify whether there are differences between the two drugs. METHOD: Retrospective observational single-centre study of CD patients on biological therapy. Variables analysed: Demographic data, Montreal classification, biological agent administered, treatment duration, presence and type of AE and the need for treatment interruption. RESULTS: Forty-nine patients were analysed, 25 treated with ADA and 24 with IFX. The groups were homogeneous in relation to the variables studied. The average follow-up period for the group treated with ADA was 19.3 months and 21.8 months for the IFX group (p = 0.585). Overall, 40% (n = 10) of patients taking ADA had AE compared with 50% (n = 12) of IFX users (p = 0.571). There was a tendency towards higher incidence of cutaneous and infusion reactions in the IFX group and higher incidence of infections in the ADA treated group, although without significant difference. CONCLUSIONS: No difference was found in the AE prevalence and profile between ADA and IFX CD patients in the population studied.
Main Authors: | Kotze,Paulo Gustavo, Akiyoshi,Fernando Kenji, Luvizotto,Mateus, Olandoski,Márcia, Kotze,Lorete Maria da Silva, Coy,Cláudio Saddy Rodrigues |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Brasileira de Coloproctologia
2013
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2237-93632013000100033 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ADALIMUMAB FOR MAINTENANCE THERAPY FOR ONE YEAR IN CROHN’S DISEASE: results of a Latin American single-center observational study
by: KOTZE,Paulo Gustavo, et al.
Published: (2014) -
SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB
by: BAU,Mariella, et al.
Published: (2017) -
Adalimumab in the induction of Crohn's disease remission: results of a Brazilian multicenter case series
by: Kotze,Paulo Gustavo, et al.
Published: (2011) -
Comparison between infliximab and adalimumab in the treatment of perianal fistulas in Crohn's disease
by: Santos,Carlos Henrique Marques dos
Published: (2014) -
Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease
by: Taxonera,Carlos, et al.
Published: (2017)